当前位置:
X-MOL 学术
›
Ann. Surg.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough?
Annals of Surgery ( IF 9 ) Pub Date : 2021-9-11 , DOI: 10.1097/sla.0000000000005064 Roi Weiser 1 , Efstathia Polychronopoulou 2 , Yong-Fang Kuo 2 , Waqar Haque 3 , Sandra S Hatch 4 , Douglas S Tyler 1, 5 , William J Gradishar 6 , V Suzanne Klimberg 1, 5
Annals of Surgery ( IF 9 ) Pub Date : 2021-9-11 , DOI: 10.1097/sla.0000000000005064 Roi Weiser 1 , Efstathia Polychronopoulou 2 , Yong-Fang Kuo 2 , Waqar Haque 3 , Sandra S Hatch 4 , Douglas S Tyler 1, 5 , William J Gradishar 6 , V Suzanne Klimberg 1, 5
Affiliation
To identify subgroups of hormone receptor-positive (HR+) breast cancer patients that might not benefit from adding endocrine therapy (ET) to their local treatment.
中文翻译:
早期激素受体阳性乳腺癌内分泌治疗的降级:何时局部治疗就足够了?
确定激素受体阳性 (HR+) 乳腺癌患者的亚组,这些患者可能无法从在局部治疗中添加内分泌治疗 (ET) 中获益。
更新日期:2021-09-11
中文翻译:
早期激素受体阳性乳腺癌内分泌治疗的降级:何时局部治疗就足够了?
确定激素受体阳性 (HR+) 乳腺癌患者的亚组,这些患者可能无法从在局部治疗中添加内分泌治疗 (ET) 中获益。